Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 6
Submit an article Journal homepage
585
Views
15
CrossRef citations to date
0
Altmetric
Psoriasis

Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department

Hélène RocheDepartment of Dermatology, University Hospital and EA3181, University of Franche Comté, Besançon, France;
,
Kevin BouillerDepartment of Internal Medicine, University Hospital, Besançon, France;
,
Eve PuzenatDepartment of Dermatology, University Hospital and EA3181, University of Franche Comté, Besançon, France;
,
Elise DevezaDepartment of Dermatology, University Hospital and EA3181, University of Franche Comté, Besançon, France;
,
Blandine RocheDepartment of Dermatology, University Hospital and EA3181, University of Franche Comté, Besançon, France;
,
Fabien PelletierDepartment of Dermatology, University Hospital and EA3181, University of Franche Comté, Besançon, France;
,
Alison van de LaakDepartment of Dermatology, University Hospital and EA3181, University of Franche Comté, Besançon, France;
,
Anne Sophie DupondDepartment of Dermatology, General Hospital, Trévenans, France
,
Charlée NardinDepartment of Dermatology, University Hospital and EA3181, University of Franche Comté, Besançon, France;
&
François AubinDepartment of Dermatology, University Hospital and EA3181, University of Franche Comté, Besançon, France; Correspondence[email protected]
 show all
Pages 540-544 | Received 23 Apr 2018, Accepted 16 May 2018, Published online: 08 Apr 2019

References

  • Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68:64–72.
  • Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170:261–273.
  • Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs. conventional systemic therapies. J Drugs Dermatol. 2014;13:848–853.
  • van den Reek JM, Zweegers J, Kievit W, et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol. 2014;171:1189–1196.
  • Bonafede M, Johnson BH, Fox KM, et al. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24:369–373.
  • Esposito M, Gisondi P, Cassano N, et al. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169:666–672.
  • Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172:244–252.
  • Philippe L, Badie J, Faller JP, et al. Fatal thrombotic thrombocytopenic purpura in a psoriasis patient treated with ustekinumab and methotrexate. Acta Derm Venerol. 2015;95:495–496.
  • Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74:851–861.
  • Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational Cohort study from the British association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015;135:2632–2640.
  • Maul JT, Djamei V, Kolios AGA, et al. Efficacy and survival of systemic psoriasis treatments: an analysis of the Swiss Registry SDNTT. Dermatology. 2016;232:640–647.
  • Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148–1158.
  • Vilarrasa E, Notario J, Bordas X, et al. ORBIT (outcome and retention rate of biologic treatments for psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74:1066–1072.
  • Dávila-Seijo P, Dauden E, Carretero G, et al. BIOBADADERM Study Group. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016;30:1942–1950.
  • Zweegers J, Groenewoud JMM, van den Reek JMPA, et al. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol. 2017;176:1001–1009.
  • Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–519.
  • Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137:1646–1654.
  • Sbidian E, Mezzarobba M, Weill A, et al. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019;180:86–93.
  • Carrascosa JM, van Doorn MB, Lahfa M, et al. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol. 2014;28:1424–1430.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.